DHR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

6.79B

+3.79%

2.139

-0.07%

6.00B

+4.43%

2.003

+6.56%

6.16B

+3.83%

1.972

+9.55%

Estimates Revision

The market is revising Downward the revenue expectations for Danaher Corporation (DHR) for FY2025, with the revenue forecasts being adjusted by -0.75% over the past three months. During the same period, the stock price has changed by 14.93%.

Revenue Estimates for FY2025

Revise Downward

-0.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.78%

In Past 3 Month

Stock Price

Go Up

+14.93%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 246.09 USD with a low forecast of 220.00 USD and a high forecast of 270.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

220.00

Averages

246.09

High

270.00

Current: 0.000

Low

220.00

Averages

246.09

High

270.00

TD Cowen

Buy

maintain

$260 -> $270

2026-01-07

New

Reason

TD Cowen

Price Target

$260 -> $270

2026-01-07

New

maintain

Buy

Reason

TD Cowen raised the firm's price target on Danaher to $270 from $260 and keeps a Buy rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.

Guggenheim

NULL -> Buy

maintain

$250 -> $275

2026-01-05

New

Reason

Guggenheim

Price Target

$250 -> $275

2026-01-05

New

maintain

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Danaher to $275 from $250 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.

Evercore ISI

Vijay Kumar

Outperform

maintain

$245 -> $250

2026-01-05

New

Reason

Evercore ISI

Vijay Kumar

Price Target

$245 -> $250

2026-01-05

New

maintain

Outperform

Reason

Evercore ISI analyst Vijay Kumar raised the firm's price target on Danaher to $250 from $245 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

BofA

Buy

maintain

$250 -> $265

2025-12-15

Reason

BofA

Price Target

$250 -> $265

2025-12-15

maintain

Buy

Reason

BofA raised the firm's price target on Danaher to $265 from $250 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Wells Fargo

Equal Weight

maintain

$230 -> $240

2025-12-15

Reason

Wells Fargo

Price Target

$230 -> $240

2025-12-15

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Danaher to $240 from $230 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Goldman Sachs

initiated

$265

2025-12-09

Reason

Goldman Sachs

Price Target

$265

2025-12-09

initiated

Reason

Goldman Sachs initiated coverage of Danaher with a Buy rating and $265 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.

Valuation Metrics

The current forward P/E ratio for Danaher Corp (DHR.N) is 28.42, compared to its 5-year average forward P/E of 28.64. For a more detailed relative valuation and DCF analysis to assess Danaher Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

28.64

Current PE

28.42

Overvalued PE

31.99

Undervalued PE

25.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

22.50

Current EV/EBITDA

22.70

Overvalued EV/EBITDA

24.96

Undervalued EV/EBITDA

20.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.68

Current PS

6.47

Overvalued PS

7.45

Undervalued PS

5.90

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased306.25%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DHR News & Events

Events Timeline

No data

News

4.5

01-08NASDAQ.COM

UPRO ETF Hits 52-Week High of $122.19 Amid Trading Insights

6.5

01-08Barron's

Invest in Danaher Stock: Poised to Overcome Post-Covid Challenges.

1.0

01-05PRnewswire

Danaher CEO Rainer M. Blair to Present at J.P. Morgan Healthcare Conference on January 13, 2026

People Also Watch

Frequently Asked Questions

What is Danaher Corp (DHR) stock price today?

The current price of DHR is 235 USD — it has decreased -0.24 % in the last trading day.

What is Danaher Corp (DHR)'s business?

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

What is the price predicton of DHR Stock?

What is Danaher Corp (DHR)'s revenue for the last quarter?

Danaher Corp revenue for the last quarter amounts to 6.05B USD, increased 4.40 % YoY.

What is Danaher Corp (DHR)'s earnings per share (EPS) for the last quarter?

Danaher Corp. EPS for the last quarter amounts to 1.27 USD, increased 13.39 % YoY.

What changes have occurred in the market's expectations for Danaher Corp (DHR)'s fundamentals?

How many employees does Danaher Corp (DHR). have?

Danaher Corp (DHR) has 61000 emplpoyees as of January 09 2026.

What is Danaher Corp (DHR) market cap?

Today DHR has the market capitalization of 165.99B USD.